| http://www.w3.org/ns/prov#value | - Based on the deal between PharmaEngine and Merrimack in 2011, PharmaEngine can receive royalties of 15 percent from Merrimack for sales of MM386 in Europe and Asia except Taiwan.However, Merrimack does not need to pay royalties to PharmaEngine for future sales of the drug in the US.Eyeing the potential of MM386 to treat multiple cancers, PharmaEngine estimated that potential sales of MM386 in Euro
|
